- Home
- AIMD vs MRKR Comparison
AIMD vs MRKR Comparison
Compare AIMD & MRKR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AIMD
- MRKR
- Stock Information
- Founded
- AIMD 1984
- MRKR N/A
- Country
- AIMD United States
- MRKR United States
- Employees
- AIMD N/A
- MRKR N/A
- Industry
- AIMD Biotechnology: Pharmaceutical Preparations
- MRKR Biotechnology: Pharmaceutical Preparations
- Sector
- AIMD Health Care
- MRKR Health Care
- Exchange
- AIMD Nasdaq
- MRKR Nasdaq
- Market Cap
- AIMD 9.9M
- MRKR 11.8M
- IPO Year
- AIMD N/A
- MRKR N/A
- Fundamental
- Price
- AIMD $0.55
- MRKR $1.17
- Analyst Decision
- AIMD
- MRKR Strong Buy
- Analyst Count
- AIMD 0
- MRKR 3
- Target Price
- AIMD N/A
- MRKR $13.17
- AVG Volume (30 Days)
- AIMD 197.4K
- MRKR 53.8K
- Earning Date
- AIMD 05-12-2025
- MRKR 05-14-2025
- Dividend Yield
- AIMD N/A
- MRKR N/A
- EPS Growth
- AIMD N/A
- MRKR N/A
- EPS
- AIMD N/A
- MRKR N/A
- Revenue
- AIMD $20,729.00
- MRKR $6,591,080.00
- Revenue This Year
- AIMD N/A
- MRKR N/A
- Revenue Next Year
- AIMD N/A
- MRKR N/A
- P/E Ratio
- AIMD N/A
- MRKR N/A
- Revenue Growth
- AIMD N/A
- MRKR 99.06
- 52 Week Low
- AIMD $0.40
- MRKR $0.95
- 52 Week High
- AIMD $1.46
- MRKR $5.99
- Technical
- Relative Strength Index (RSI)
- AIMD 52.13
- MRKR 47.32
- Support Level
- AIMD $0.52
- MRKR $0.99
- Resistance Level
- AIMD $0.59
- MRKR $1.25
- Average True Range (ATR)
- AIMD 0.06
- MRKR 0.10
- MACD
- AIMD 0.00
- MRKR 0.03
- Stochastic Oscillator
- AIMD 50.00
- MRKR 73.33
About AIMD Ainos Inc.
Ainos Inc is engaged in developing biologics for the treatment of human and animal diseases. The company mainly focuses on the research of the treatment of human disease indications, particularly influenza, hepatitis C, thrombocytopenia, and other indications using natural human interferon-alpha that is administered in a proprietary low-dose oral form. Its product pipeline includes VELDONA Pet cytoprotein supplements for pets, VELDONA human therapeutics for clinical use, and telehealth-friendly POCTs powered by the AI Nose technology platform.
About MRKR Marker Therapeutics Inc.
Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets.